MOC.WA

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$65M	+1851.5%	$2.40	$2.40–$2.40	—	1
2027	$125M	+92.2%	$2.60	$2.60–$2.60	—	1
2028	$9M	-92.8%	$-1.50	$-1.50–$-1.50	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

DCF fair valuemodel estimate

Intrinsic value

$0.52

Price

$7.50

Implied downside

-93%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
MOC.WAMolecure S.A.	$7.63	+3.39%	$189M	—
AWM.WAAirway Medix S.A.	$0.28	-0.36%	$32M	—
CTX.WACaptor Therapeutics Spolka Akcyjna	$72.50	+0.28%	$459M	—
GMT.WAGenomtec S.A.	$3.61	+0.00%	$62M	—
ICE.WAMedinice S.A.	$57.40	-4.17%

Molecure S.A.

Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions. The company's pipeline prominently features OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has successfully advanced through Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and sarcoidosis. Additionally, Molecure is progressing its YKL-40 program for cancer and fibrosis, OATD-02 for oncology applications, and a Deubiquitinase program. Established in 2012, this Warsaw-headquartered enterprise adopted the name Molecure S.A. in March 2022, having previously been known as OncoArendi Therapeutics S.A.

molecure.com

Employees: 102
IPO / List date: Apr 19, 2018
HQ: PL

Held by traders on TradeandTell

No one on the platform currently holds MOC.WA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in MOC.WA as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded MOC.WA yet.